Nicolas Dzamko

Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2

Xianming Deng, Nicolas Dzamko, Alan R. Prescott et al. · Nature Chemical Biology · 2011 · 431 citations · Full text

Life Sciences, Medicinal Chemistry, Pharmacology +14

14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization

R. Jeremy Nichols, Nicolas Dzamko, Nicholas A. Morrice et al. · Biochemical Journal · 2010 · 404 citations · Full text

Life Sciences, Molecular Biology, Neuroscience +13

Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser910/Ser935, disruption of 14-3-3 binding and altered cytoplasmic localization

Nicolas Dzamko, Mária Deák, Fayçal Hentati et al. · Biochemical Journal · 2010 · 388 citations · Full text

Life Sciences, Molecular Biology, Pharmacology +16

CNTF reverses obesity-induced insulin resistance by activating skeletal muscle AMPK

Matthew J. Watt, Nicolas Dzamko, Walter G. Thomas et al. · Nature Medicine · 2006 · 280 citations

Life Sciences, Biochemistry, Physiology +13

Toll-like receptor 2 is increased in neurons in Parkinson’s disease brain and may contribute to alpha-synuclein pathology

Nicolas Dzamko, Amanda M. Gysbers, Gayathri Perera et al. · Acta Neuropathologica · 2016 · 279 citations · Full text

Life Sciences, Neurobiology, Neuroscience +17